Jing

Anticancer Bioscience and DelSiTech Announce a Collaboration Agreement for the Development of Long-acting and Controlled Release Therapies in Oncology

Press ReleaseChengdu, China, May 18, 2022Anticancer Bioscience and DelSiTech Announce a Collaboration Agreement for the Development of Long-acting and Controlled Release Therapies in Oncology Chengdu, China, May 18, 2022 – Anticancer Bioscience (ACB), pioneers in synthetic lethal approaches to precision oncology, based in China, and DelSiTech Ltd, the leading silica drug delivery technology company, based in …

Anticancer Bioscience and DelSiTech Announce a Collaboration Agreement for the Development of Long-acting and Controlled Release Therapies in Oncology Read More »

Anticancer Bioscience’s CEO and Founder Dr Dun Yang Named as a 2022 In Vivo Rising Leader

Press ReleaseChengdu, China, April 19, 2022Anticancer Bioscience’s CEO and Founder Dr Dun Yang Named as a 2022 In Vivo Rising Leader Chengdu, China, April 19, 2022 – Anticancer Bioscience (ACB), pioneers in synthetic lethal approaches to precision oncology, is delighted to announce that its Founder, President and CEO, Dun Yang, PhD has been named as …

Anticancer Bioscience’s CEO and Founder Dr Dun Yang Named as a 2022 In Vivo Rising Leader Read More »

Anticancer Bioscience Identified Phytochemical Corynoline as a Prototype Structure for Developing Centrosome-declustering Therapeutics

Press ReleaseChengdu, China, January 17, 2022Anticancer Bioscience Identified Phytochemical Corynoline as a Prototype Structure for Developing Centrosome-declustering Therapeutics Chengdu, China, January 17, 2022 - The Discovery Oncology (DO) group and the Natural Product Drug Discovery (NPDD) group of Anticancer Bioscience (ACB) collaboratively published another interesting study that uncovers a novel mechanism by which a natural …

Anticancer Bioscience Identified Phytochemical Corynoline as a Prototype Structure for Developing Centrosome-declustering Therapeutics Read More »

Dr. Allen, VP of Anticancer Bioscience, Presented His Insights on Personalized / Precision Medicine at a Roundtable Discussion Organized by Pharma’s Almanac

Press ReleaseChengdu, China, January 8, 2022Dr. Allen, VP of Anticancer Bioscience, presented his insights on personalized / precision medicine at a roundtable discussion organized by Pharma's Almanac Chengdu, China, January 8, 2022 - Dr. Thaddeus Allen, VP of Translational Biology and Business Development, was invited for a roundtable discussion by Pharma’s Almanac on January 7th, …

Dr. Allen, VP of Anticancer Bioscience, Presented His Insights on Personalized / Precision Medicine at a Roundtable Discussion Organized by Pharma’s Almanac Read More »

Anticancer Bioscience Expands its R&D and Headquarters with a Relocation to Tianfu International Biotown, China

Press ReleaseChengdu, China, December 20, 2021Anticancer Bioscience Expands its R&D and Headquarters with a Relocation to Tianfu International Biotown, China Chengdu, China, December 20, 2021 - Anticancer Bioscience (ACB), pioneers in synthetic lethal approaches to precision oncology, announced today that to accommodate its growth and expansion, and on the back of its recent financing, it …

Anticancer Bioscience Expands its R&D and Headquarters with a Relocation to Tianfu International Biotown, China Read More »

Anticancer Bioscience Announces its First Granted US Patent for Synthetic Lethal Approach to Identifying Novel Cancer Treatments

PRESS RELEASEChengdu, China, September 9, 2021Anticancer Bioscience Announces its First Granted US Patent for Synthetic Lethal Approach to Identifying Novel Cancer Treatments Chengdu, China, September 9, 2021 - Anticancer Bioscience (ACB), pioneers in synthetic lethal approaches to precision oncology, announced today its first granted US patent (11104633), entitled “cancer treatment using compounds that selectively target polyploid …

Anticancer Bioscience Announces its First Granted US Patent for Synthetic Lethal Approach to Identifying Novel Cancer Treatments Read More »

Anticancer Bioscience Appoints Leader in Oncology Drug Development, Dr. Hong Liu, as US-based VP of Clinical Development

PRESS RELEASEChengdu, China, July 14, 2021Anticancer Bioscience Appoints Leader in Oncology Drug Development, Dr. Hong Liu, as US-based VP of Clinical Development Chengdu, China, July 14, 2021 - Anticancer Bioscience (ACB), pioneers in synthetic lethal approaches to precision oncology, announced today the appointment of Dr. Hong Liu as VP of Clinical Development. A physician-scientist, he …

Anticancer Bioscience Appoints Leader in Oncology Drug Development, Dr. Hong Liu, as US-based VP of Clinical Development Read More »